Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19
Francesca Capon, PhD
King’s College London
London, UK
IPC Councilor
Publication
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Matthew T. Patrick, MEng PhD, Haihan Zhang, MS, Rachael Wasikowski, MS, Errol P. Prens, MD, PhD, Stephan Weidinger, MD, PhD, Johann E. Gudjonsson, MD, PhD, James T. Elder, MD, PhD, Kevin He, PhD, and Lam C. Tsoi, PhD. J Allergy Clin Immunol. 2021 Jan 21 doi: 10.1016/j.jaci.2021.01.006 [Epub ahead of print]
Commentary
Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.
An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1115 of whom had been diagnosed with COVID-19. After adjusting their analysis for the age, ethnicity, body mass index, and socioeconomic status of participants, they found that having an inflammatory skin disorder (acne, atopic dermatitis, or psoriasis) conferred an increased risk of COVID-19 while reducing the likelihood of requiring mechanical ventilation.
The authors next analyzed publicly available expression data and observed a significant overlap between the genes that are up-regulated in inflammatory skin diseases and those that are induced by SARS-CoV2 infection in bronchial epithelial cells. Of note, the shared genes were mostly involved in epidermal barrier function and innate antiviral responses.
In the final stage of the study, the authors re-examined published genome-wide association studies and found a marker that was associated with susceptibility to both psoriasis and COVID-19. Interestingly, the variant maps in proximity to S100A12, a gene that is up-regulated in psoriatic lesions and in SARS-CoV2 infected cells.
These observations suggest a link between skin inflammation and COVID-19 susceptibility. The authors speculate that in individuals with psoriasis or atopic dermatitis, SARS-CoV2 could enter the organism through the skin, exploiting defects in epidermal barrier function. Progression to severe disease would then be hindered by the activation of immune responses at sites of inflammation. While these hypotheses could be tested in animal models, the authors acknowledge that the underlying observations will need to be replicated in further genetic and epidemiological studies.
Reference:
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. MT Patrick et al. J Allergy Clin Immunol. Epub ahead of print: 20th Jan 2021. DOI: https://doi.org/10.1016/j.jaci.2021.01.006
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
Subscribe to the IPC Newsletter